Latest News
2025.2.10
First patient was enrolled in a Phase 3 clinical trial for pancreatic cancer in Japan.
2024.8.26
We submitted a Phase 3 clinical trial notification for pancreatic cancer in Japan to the Pharmaceuticals and Medical Devices Agency (PMDA).
2024.7.18
Results from preclinical study will be presented by Dr. Juanjuan Ye at the 83rd Annual Meeting of the Japanese Cancer Association (Fukuoka, September 19-21, 2024).
Title：Pancreatic tumor suppression by anti-PD-1 antibody and stroma modifying RNA oligonucleotide STNM01 in mice
Presentation No.：E14-4
Presentation Type：English Oral Session
Date and Time：Sep. 20 (Fri.) 13:00-14:15
The 83rd Annual Meeting of the Japanese Cancer Association
https://site.convention.co.jp/jca2024/en/
2024.6.20
Results from preclinical study were published by Dr. Juanjuan Ye in Molecular Therapy Oncology.
Title: Intra-tumoral administration of CHST15 siRNA remodels tumor microenvironment and augments tumor-infiltrating T cells in pancreatic cancer.
2024.5.31
Results from preclinical study were presented by Dr. Juanjuan Ye at American Society of Clinical Oncology (ASCO) annual meeting 2024.
Title: Robust pancreatic tumor suppression by a novel combination treatment with anti-PD-1 immune checkpoint antibody and stroma modifying RNA oligonucleotide STNM01 in mice.
https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e14630
2024.5.21
Results from preclinical study were presented by Dr. Juanjuan Ye at the Digestive Disease Week (DDW) annual meeting 2024.
Title：LOCOREGIONAL INJECTION OF RNA OLIGONUCLEOTIDE TARGETING CARBOHYDRATE SULFOTRANSFERASE 15 DIMINISHES BOTH TUMORAL AND LYMPH NODE MDSCS AND ACCELERATES T CELL INFILTRATION IN PANCREATIC TUMOR IN MICE
Presentation Type：Poster Session
Date and Time：May 21, 2024 from 12:30 PM to 1:30 PM EDT (UTC –4)